AMGEN LIMITED
Company Information
- Company Number
- 02354269
- Registered Address
- 216 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, England, CB4 0WA
- Status
- Active
- Employee Count
- 558
- Turnover
- £305,203,000
- EBITDA
- £16,641,000
Additional Details
- Website
- https://amgen.com/
- Company Type
- Private limited Company
- Incorporated On
- 1 March 1989
- Nature of Business
- 72110 - Research and experimental development on biotechnology
- Industries
- Life Sciences And Medical Technology
- Region
- East of England
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 26 Jul 2025 | 54 | 35% | 38% | 27% | 5% |
| 01 Jan 2024 - 30 Jun 2024 | 07 Jul 2025 | 52 | 44% | 41% | 15% | 8% |
| 01 Jan 2023 - 30 Jun 2023 | 27 Jul 2023 | 55 | 41% | 45% | 14% | 11% |
| 01 Jul 2022 - 31 Dec 2022 | 20 Jan 2023 | 52 | 42% | 45% | 14% | 8% |
| 01 Jan 2022 - 30 Jun 2022 | 25 Jul 2022 | 61 | 34% | 48% | 17% | 7% |
| 01 Jan 2020 - 30 Jun 2020 | 28 Jul 2020 | 48 | 46% | 42% | 12% | 11% |
| 01 Jul 2019 - 31 Dec 2019 | 29 Jan 2020 | 38 | 59% | 34% | 7% | 10% |
| 01 Jan 2019 - 30 Jun 2019 | 29 Jul 2019 | 35 | 58% | 34% | 8% | 10% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 37 | 60% | 31% | 9% | 10% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Undisputed invoices will be payable by Amgen within sixty days of invoice date.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
60
Dispute Resolution Process
Any discrepancies between invoice and delivery/receipt of goods or services are fully investigated internally and the findings discussed in full with the supplier, with a view of resolving the difference and/or negotiating settlement.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
AMGEN LIMITED is a leading biotechnology company that focuses on developing and manufacturing innovative medicines for serious diseases. The company was founded in 1980 and has its registered office address in Cambridge, United Kingdom.
The company's main activities include researching, developing, and manufacturing biologic medicines for diseases such as cancer, cardiovascular diseases, and inflammatory disorders. They also offer support services for patients and healthcare professionals.
AMGEN LIMITED is committed to sustainability and has implemented various initiatives to reduce their environmental impact. This includes reducing greenhouse gas emissions, conserving water and energy, and implementing sustainable packaging practices.
One of the key products of AMGEN LIMITED is Enbrel, which is used to treat inflammatory conditions such as rheumatoid arthritis and psoriasis. They also have a range of other medicines for different diseases, including Prolia for osteoporosis and Neulasta for cancer treatment.
The key people at AMGEN LIMITED include the CEO, Robert A. Bradway, and the Chief Scientific Officer, David M. Reese. They lead a team of dedicated scientists, researchers, and employees who work towards developing life-changing medicines for patients.
For more information on their products and services, as well as their sustainability efforts, one can visit their website at www.amgen.co.uk. The website also provides contact information for general inquiries and customer support. AMGEN LIMITED is dedicated to improving the lives of patients and making a positive impact on society through their innovative medicines and sustainable practices.
